IL17 (IL17A) Human shRNA Plasmid Kit (Locus ID 3605)

CAT#: TR312190

IL17A - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided

Specifications

Product Data

• Locus ID: 3605
• Synonyms: CTLA-8; CTLA8; IL-17; IL-17A; IL17; ILA17
• Vector: pRS
• E. coli Selection: Ampicillin
• Mammalian Cell Selection: Puromycin
• Format: Retroviral plasmids
• Kit Components: IL17A - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 3605). 5µg purified plasmid DNA per construct
  29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
• RefSeq: NM_002190, NM_002190.1, NM_002190.2, BC066251, BC066252, BC066253, BC067503, BC067504, BC067505, NM_002190.3
• UniProt ID: Q16552
• Summary: This gene is a member of the IL-17 receptor family which includes five members (IL-17RA-E) and the encoded protein is a proinflammatory cytokine produced by activated T cells. IL-17A-mediated downstream pathways induce the production of inflammatory molecules, chemokines, antimicrobial peptides, and remodeling proteins. The encoded protein elicits crucial impacts on host defense, cell trafficking, immune modulation, and tissue repair, with a key role in the induction of innate immune defenses. This cytokine stimulates non-hematopoietic cells and promotes chemokine production thereby attracting myeloid cells to inflammatory sites. This cytokine also regulates the activities of NF-kappaB and mitogen-activated protein kinases and can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). IL-17A plays a pivotal role in various infectious diseases, inflammatory and autoimmune disorders, and cancer. High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The lung damage induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is to a large extent, a result of the inflammatory response promoted by cytokines such as IL17A. [provided by RefSeq, Sep 2020]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).